Stock Ratings / Health Care / BSEM / financials

CVM (39) EVAX (58) GNTA (62) MGX (41) ⌘ Pro Terminal →

BioStem Technologies Inc. (BSEM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is BioStem Technologies Inc. (BSEM)?

In FY 2025 (10-K), BSEM converted $47.5M of revenue into a 93.6% gross margin, 0% operating margin, and $6.6M in free cash flow (13.9% FCF margin).

$1.29 -14.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BioStem Technologies Inc. (BSEM) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $24.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BSEM)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BSEM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$6.6M (13.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $69.7M

FY25

Rev $47.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$47.5M	93.6%	-1.5%	-$6.6M	$6.6M	-5.7%
FY 2024	$69.7M	80.3%	44.7%	$31.0M	$24.0M	95%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BSEM)

✓Walkthrough of BSEM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BSEM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.40%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.29H $1.29L $1.11C $1.29VOL 145.4K

RES: $5.98SUP: $0.97SMA50: $3.08SMA200: $4.20

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BSEM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BSEM Butterfly Map → + Track BSEM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -31.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BSEM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BSEM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BSEM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BSEM)

Health Care Rank #762 of 1016 ⚔️ CVM vs BSEM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BSEM vs. CVM, EVAX, GNTA, MGX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioStem Technologies Inc. (BSEM) ranks #762 by composite RQD confidence (37/100, grade D-) and #821 by equity capitalization ($24.1M). Within this direct 5-issuer industry benchmark cohort, BSEM leads on earnings valuation at N/A trailing P/E, while BSEM leads on capital efficiency and profitability with -5.7% ROIC and 93.6% gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with BSEM at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BSEM ACTIVE BioStem Technologies Inc.	D-	37/100	—	93.6%	-5.7%	-14.57%	$24.1M	Benchmark Subject
CVM Cel-Sci Corporation	D-	39/100	—	—	-35.0%	-6.25%	$26.4M	/cvm-vs-bsem →
EVAX Evaxion A/S	D+	58/100	—	—	—	-0.96%	$27.8M	/evax-vs-bsem →
GNTA Genenta Science S.p.A.	C	62/100	—	—	—	+2.48%	$29.9M	/gnta-vs-bsem →
MGX Metagenomi Therapeutics Inc.	D-	41/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-bsem →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001658678

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioStem Technologies Inc. (BSEM) reported GAAP revenue of $47.5M (-31.8% vs. FY2024 revenue of $69.7M ) , GAAP net income of -$6.6M, operating cash flow of $9.9M, and free cash flow of $6.6M (-72.6% YoY). On the balance sheet, BSEM closed FY2025 with $50.0M in total assets against $0 in total debt (Altman Z-Score: 2.44, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$47.5M	-$6.6M	$9.9M	$6.6M	$50.0M	—
FY2024 (FY)	2024-12-31	$69.7M	$31.0M	$24.5M	$24.0M	$58.3M	—

3. BSEM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BSEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioStem Technologies Inc. (NASDAQ: BSEM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.29 (-14.57% 1D, market cap $24.1M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BSEM ranks #762 in composite RQD confidence.

How does BSEM compare to CVM and EVAX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BSEM carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 93.6%, and ROIC of -5.7%. By comparison, CVM (Cel-Sci Corporation) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $26.4M) and EVAX (Evaxion A/S) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $27.8M). Among the 5-stock peer group, BSEM leads on earnings multiple (N/A) while BSEM leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BSEM?

Per BSEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658678), BioStem Technologies Inc. generated $47.5M in revenue (-31.8% YoY), -$6.6M in net income, and $6.6M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BSEM trading relative to its 50-day, 200-day, and 52-week technical levels?

BSEM last traded at $1.29 (-14.57% on volume of 263,740 shares), positioning the stock -58.12% below its 50-day simple moving average ($3.08) and -69.29% below its 200-day simple moving average ($4.20). Across its 52-week range of $1.11 to $8.40, BSEM sits at the 2.5% percentile with a 14-day RSI of 21.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.13 to $1.45).